GSA Capital Partners LLP Has $71,000 Stock Holdings in Hookipa Pharma Inc (NASDAQ:HOOK)

GSA Capital Partners LLP trimmed its position in Hookipa Pharma Inc (NASDAQ:HOOK) by 86.1% in the third quarter, Holdings Channel.com reports. The institutional investor owned 16,609 shares of the company’s stock after selling 103,028 shares during the period. GSA Capital Partners LLP’s holdings in Hookipa Pharma were worth $71,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the company. Virtu Financial LLC bought a new position in Hookipa Pharma in the 1st quarter worth $31,000. Renaissance Technologies LLC boosted its holdings in Hookipa Pharma by 38.4% during the second quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock valued at $179,000 after acquiring an additional 83,800 shares during the period. Finally, Acadian Asset Management LLC grew its position in shares of Hookipa Pharma by 12.3% in the second quarter. Acadian Asset Management LLC now owns 991,106 shares of the company’s stock valued at $586,000 after purchasing an additional 108,844 shares during the last quarter. 63.88% of the stock is owned by institutional investors.

Hookipa Pharma Price Performance

Shares of Hookipa Pharma stock opened at $2.29 on Tuesday. The company has a market cap of $27.56 million, a PE ratio of -0.61 and a beta of 0.84. The firm has a fifty day moving average price of $3.79 and a two-hundred day moving average price of $5.44. Hookipa Pharma Inc has a fifty-two week low of $2.08 and a fifty-two week high of $11.30.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. JMP Securities cut their price objective on Hookipa Pharma from $24.00 to $7.00 and set a “market outperform” rating for the company in a research report on Thursday, November 21st. Royal Bank of Canada cut their price target on Hookipa Pharma from $50.00 to $48.00 and set an “outperform” rating for the company in a report on Friday, November 15th.

Hookipa Pharma Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.